The Nolotil, one of the best-known painkillers in Spain, is once again under healthcare scrutiny after an investigation examined nine deaths associated with its use in the province of Alicante over a two-year period. The medicine contains metamizole, an active ingredient indicated for certain types of pain and fever episodes, but which can also cause serious adverse reactions, including agranulocytosis, an alteration that significantly reduces certain defensive cells in the blood.
The study, published by El País on November 16, analyzes cases detected during 2016 and 2017 in five health departments in Alicante. Seven of the nine who died were British patients. The findings reopen the debate about the safety of the medicine and differences in risk among population groups, although Nolotil continues to be authorized in Spain under the conditions established by the Spanish Agency for Medicines and Health Products (AEMPS).
What Nolotil is for
The active ingredient in Nolotil is metamizole, a medicine with analgesic, antipyretic, and antispasmodic properties. Its use is authorized to treat certain painful conditions and fever episodes that meet the indications included in its technical data sheet.
Among its uses are moderate to severe acute pain of different origins and high fever that does not respond adequately to other measures or medicines, always according to medical assessment.
It is a medicine subject to medical prescription. Its use must be adjusted to the dose and duration indicated by a healthcare professional, taking into account each patient’s medical history and risk factors.
What agranulocytosis is and why it can be dangerous
Agranulocytosis is a serious blood disorder characterized by a marked decrease in certain white blood cells, especially neutrophils, which are involved in the body’s defense against infections.
When these cells decrease, the patient may be exposed to serious and potentially fatal infections.
The AEMPS warns that this reaction may occur during treatment with metamizole and even shortly after stopping it. In addition, it does not necessarily depend on the administered dose.
What warning symptoms are listed in the technical data sheet
The official information on the medicine identifies several symptoms that may indicate possible agranulocytosis:
- Fever or chills that appear during treatment.
- Sore throat and discomfort when swallowing.
- Blisters or painful lesions on the mucous membranes of the mouth, nose, or throat.
- Painful abnormalities in the genital or anal area.
- Signs of infection or unexpected deterioration of the overall condition.
The AEMPS indicates that, in the presence of symptoms compatible with agranulocytosis, treatment must be interrupted and immediate medical attention sought. The technical information sheet also includes the urgent performance of a blood test to check the number of blood cells.
What the new study has found about Nolotil
The research published by El País examines cases of agranulocytosis related to metamizole during 2016 and 2017 in the health departments of Denia, Villajoyosa, Torrevieja, San Juan y Orihuela.
The work pays special attention to the differences observed between British and Spanish patients. According to the information that has been released, seven of the nine identified deaths corresponded to British citizens.
These results must be interpreted together with the study design and its limitations. The existence of a known risk and the identification of associated deaths do not allow the individual probability of suffering an adverse reaction to be calculated directly.
Is Nolotil prohibited in Spain?
Nolotil is not prohibited in Spain. The medication continues to be authorized, although subject to prescription and to the safety warnings included by the AEMPS.
The agency has assessed the risk of agranulocytosis on different occasions and maintains recommendations to reduce exposure of patients with risk factors and to promote the early identification of possible serious reactions.
Those who have doubts about a prescribed treatment should consult their doctor or pharmacist before modifying it, unless they present the warning symptoms for which the AEMPS itself indicates immediate interruption and the search for medical assistance.